Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus (Albumin-bound) + Fulvestrant in HR+/HER2- Advanced Breast Cancer
NCT06929325Phase 3Not yet recruiting
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Apr 2025
- Primary completion
- Oct 2026
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of nab-sirolimus in Hormone-Receptor-Positive Breast Cancer (2 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoint: Progression-free Survival. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
nab-sirolimus
03
Conditions
Hormone-Receptor-Positive Breast Cancer
Beyond the preview
Go deeper on NCT06929325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06929325.